Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novartis AG Common Stock (NY:NVS)

109.59 +1.13 (+1.04%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
45 46 Next >
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
From Erasca, Inc.
Via GlobeNewswire
Novartis' Rare Blood Disorder Therapy Aces Second Late-Stage Trial
Via Benzinga
3 Hot Stocks That Could Live Up to Their Lofty Valuations
These companies have long runways of growth ahead 
Via The Motley Fool
MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs
Via Benzinga
Novartis' Kisqali Prolongs Progression Free Survival Benefit In Metastatic Breast Cancer Versus Chemo
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
These two rank among the 10 largest pharmaceutical companies on the planet. 
Via The Motley Fool
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member
Via Investor Brand Network
Exposures COVID-19
Why CSL Ltd Stock Could Be Worth a Look
FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment. 
Via MarketBeat
Exposures Product Safety
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
By Rachael Green, Benzinga 
Via News Direct
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break... 
Via TheNewswire.com
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
Longwood Healthcare Leaders to Bring Together Several Hundred Top Biotech and Pharmaceutical Leaders on Jan. 5-6, 2023
Longwood Fund, an early-stage life science venture firm, will convene several hundred top biotech and pharmaceutical leaders at its Pre-JPM Longwood Healthcare Leaders meeting, hosted virtually via... 
Via Newswire.com
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
3 Biotech Stocks Smart Investors Should Be Buying Up Now
These three biotech stocks could be among the best ways to play this uncertain market for those looking for long-term growth. 
Via InvestorPlace
Novartis' Malaria Treatment Candidate To Move Forward With Phase 3 Development Next Year
Via Benzinga
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf Cell Therapy Candidate, AllocetraTM
On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dose 
Via Benzinga
TEVA Stock Alert: What to Know About Teva Pharmaceuticals’ New CEO
Teva Pharmaceuticals (TEVA) stock is sliding on Monday after the company announced Richard Francis as its newest president and CEO. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Thoughts For Thursday: Correction Day!
The market remains agitated and it looks like it may be a long week from here to Thanksgiving. Yesterday the market remained chiefly in corrective mode, as it was down from the outset. 
Via Talk Markets
Novartis Mulls Disposing Its Non-Core Ophthalmology and Respiratory Units
Novartis AG (NYSE: NVS) is reportedly weighing divesting non-core assets as it seeks to raise money to invest in cutting-edge medicines, people familiar with the matter said. 
Via Benzinga
BioNTech Plans To Set Up Singapore Based mRNA Plant By End Of 2023
Via Benzinga
Should Income Investors Buy This High-Yielding Dividend Stock?
Novartis' product portfolio and pipeline bode well for its future. 
Via The Motley Fool
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
Drug Repurposing Market to Eyewitness Huge Growth by 2027 : Allergan, Astellas Pharma, Biovista, NuMedii
Stay up-to-date with Drug Repurposing Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Exposures Product Safety
Leading Data Analytics Company Vizlib Gains ISO 27001 Certification
About Vizlib Vizlib has revolutionised the way businesses of every size can get more from their data analytics investment into Qlik. With over 1,000 enterprise and public sector clients across the... 
Via PRUnderground
2 Biotech Stocks That Could Make You Richer
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors. 
Via The Motley Fool
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
Via Benzinga
3 High-Yielding Dividend Stocks That You Can Buy and Hold Forever
These stocks are all trading close to their 52-week lows. 
Via The Motley Fool
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.